Näytä suppeat kuvailutiedot

dc.contributor.authorWirta, Erkki-Ville
dc.contributor.authorSzeto, Säde
dc.contributor.authorKoppatz, Hanna
dc.contributor.authorNordin, Arno
dc.contributor.authorMäkisalo, Heikki
dc.contributor.authorArola, Johanna
dc.contributor.authorSirén, Jukka
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorBöhm, Jan
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorSallinen, Ville
dc.contributor.authorSeppälä, Toni T.
dc.date.accessioned2024-05-02T12:02:50Z
dc.date.available2024-05-02T12:02:50Z
dc.date.issued2024
dc.identifier.citationWirta, E.-V., Szeto, S., Koppatz, H., Nordin, A., Mäkisalo, H., Arola, J., Sirén, J., Ahtiainen, M., Böhm, J., Mecklin, J.-P., Sallinen, V., & Seppälä, T. T. (2024). High immune cell infiltration predicts improved survival in cholangiocarcinoma. <i>Frontiers in Oncology</i>, <i>14</i>, Article 1333926. <a href="https://doi.org/10.3389/fonc.2024.1333926" target="_blank">https://doi.org/10.3389/fonc.2024.1333926</a>
dc.identifier.otherCONVID_213449292
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/94645
dc.description.abstractBackground: Antitumoral immune response has a crucial role in constraining cancer. However, previous studies on cholangiocarcinoma (CCA), a rare and aggressive cancer, have reported contradictory findings on the prognostic impact of tumor-infiltrating T-lymphocytes. We aimed to clarify the effect of tumor-infiltrating CD3+ and CD8+ lymphocytes and PD-1/PD-L1 expression on CCA prognosis. Methods: CD3+, CD8+, and PD-1+ lymphocyte densities, as well as PD-L1 expression rate were analyzed from stained tissue microarray samples from the tumor center and invasive margin of 47 cholangiocarcinomas. The association of CD3+ and CD8+ based Immune cell score (ICS) and its components with overall survival was evaluated, adjusting for age, sex, TNM stage, radicality of surgery, tumor location, and PD-L1 expression on immune cells. Results: Low ICS was a strong independent prognostic factor for worse overall survival (Hazard ratio 9.27, 95% confidence interval 2.72-31.64, P<0.001). Among the ICS components, high CD8+ lymphocyte infiltration at the tumor center had the most evident impact on patient outcome. PD-1 and PD-L1 expression on immune cells did not have a significant impact on overall survival alone; however, PD-L1 positivity seemed to impair survival for ICSlow subgroup. Conclusion: Identifying patient subgroups that could benefit from immunotherapy with PD-1/PD-L1 pathway blockade may help improve treatment strategies for this aggressive cancer. Our findings highlight the importance of evaluating the immune contexture in cholangiocarcinoma, as ICS serves as a strong independent prognostic and selective factor for patients who might benefit from immunotherapy.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology
dc.rightsCC BY 4.0
dc.subject.othercholangiocarcinoma
dc.subject.othertumor-infiltrating T-lymphocytes
dc.subject.otherimmune cell score
dc.subject.otherPD-1
dc.subject.otherPD-L1
dc.titleHigh immune cell infiltration predicts improved survival in cholangiocarcinoma
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202405023271
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2234-943X
dc.relation.volume14
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 the Authors
dc.rights.accesslevelopenAccessfi
dc.subject.ysoimmuunijärjestelmä
dc.subject.ysosyöpäsolut
dc.subject.ysosyöpähoidot
dc.subject.ysoruoansulatuselinten taudit
dc.subject.ysoimmuunihoito
dc.subject.ysoT-imusolut
dc.subject.ysosyöpätaudit
dc.subject.ysolymfosyytit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p16041
jyx.subject.urihttp://www.yso.fi/onto/yso/p23898
jyx.subject.urihttp://www.yso.fi/onto/yso/p27422
jyx.subject.urihttp://www.yso.fi/onto/yso/p2057
jyx.subject.urihttp://www.yso.fi/onto/yso/p12660
jyx.subject.urihttp://www.yso.fi/onto/yso/p38968
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p2766
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.3389/fonc.2024.1333926
jyx.fundinginformationThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. TS is supported by funding from the Academy of Finland and iCAN Precision Medicine Flagship of Academy of Finland (338657), and research grants by Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation (220174), Emil Aaltonen Foundation, Cancer Foundation Finland, Relander Foundation, and state research funding (TYH2022323). VS obtained funding for the study from Helsinki University Hospital Research Grants (TYH2021228). The funding bodies had no role in writing the article.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0